Citations

Clear

150 citation(s) found for "Singh, Ravinder".

Center of Mass Calculation in Combination with MS/MS Allows Robust Identification of Single Amino Acid Polymorphisms in Clinical Measurements of Insulin-Like Growth Factor-1
Maus, Anthony , Kemp, Jennifer, Milosevic, Dragana , Renuse, Santosh , Pandey, Akhilesh , Grebe, Stefan K., Grebe, Stefan K G, Pandey, Akhilesh , Maus, Anthony D , Singh, Ravinder J.

Mayo Clinic

Journal of Proteome Research | November 18, 2019 | Volume: 19 | Issue: 1 | Pages: 186-193

10.1021/acs.jproteome.9b00494 | PMID 31736316 Get It

SAT-390 New Cortisol Threshold for Diagnosis of Adrenal Insufficiency After Cosyntropin Stimulation Testing Using the Elecsys Cortisol II, Access Cortisol, and LC-MS/MS Assays
Javorsky, Bradley R. , Colón-Franco, Jessica M , Findling, James W. , Carroll, Ty B , Algeciras‐Schimnich, Alicia , Singh, Ravinder J.

Mayo Clinic

Journal of the Endocrine Society | May 10, 2019 | Volume: 3 | Issue: Supplement_1 | Pages: No page available

10.1210/js.2019-sat-390 Get It

Catecholamine and Metanephrine Levels in Breast Milk Before and After Paraganglioma Resection
Dodd, Sarah E. , Martin, Yvette N. , Singh, Ravinder J.

Mayo Clinic

Breastfeeding Medicine | March 15, 2019 | Volume: 14 | Issue: 4 | Pages: 276-277

10.1089/bfm.2019.0018 | PMID 30874459 Get It

Adrenal Cortical Carcinoma Associated With Lynch Syndrome: A Case Report and Review of Literature
Kaur, Ravinder Jeet , Pichurin, Pavel N. , Hines, Jolaine M., Grebe, Stefan K., Singh, Ravinder J. , Bancos, Irina

Mayo Clinic

Journal of the Endocrine Society | March 5, 2019 | Volume: 3 | Issue: 4 | Pages: 784-790

10.1210/js.2019-00050 | PMID 30963136 Get It

Obesity Decreases Hepatic 25-Hydroxylase Activity Causing Low Serum 25-Hydroxyvitamin D
Long, Caela, Casella, Alex, O’Lear, Lauren, Caplan, Ilana, Lai, Meizan , Sasson, Issac, Makowski, Andrew J., Simmons, Rebecca A. , Levine, Michael A. , Roizen, Jeffrey D. , Singh, Ravinder J. , Levine, M A

Mayo Clinic

Journal of Bone and Mineral Research | February 21, 2019 | Volume: 34 | Issue: 6 | Pages: 1068-1073

10.1002/jbmr.3686 | PMID 30790351 Get It

ABSTRACT Normal vitamin D homeostasis is critical for optimal health; nevertheless, vitamin D deficiency is a worldwide public health problem. Vitamin D insufficiency is most commonly due to inadequate cutaneous synthesis of cholecalciferol and/or insufficient intake of vitamin D, but can also arise as a consequence of pathological states such as obesity. Serum concentrations of 25(OH)D (calcidiol) are low in obesity, and fail to increase appropriately after vitamin D supplementation. Although sequestration of vitamin D in adipose tissues or dilution of ingested or cutaneously synthesized vitamin D in the large fat mass of obese patients has been proposed to explain these findings, here we investigate the alternative mechanism that reduced capacity to convert parent vitamin D to 25(OH)D due to decreased expression of CYP2R1, the principal hepatic vitamin D 25-hydroxylase. To test this hypothesis, we isolated livers from female mice of 6 to 24 weeks of age, weaned onto either a normal chow diet or a high-fat diet, and determined the abundance of Cyp2r1 mRNA using digital droplet-quantitative PCR. We observed a significant (p < 0.001) decrease in Cyp2r1 mRNA in the liver of high-fat diet–fed mice relative to lean-chow–fed female mice. Moreover, there was a significant (p < 0.01) relationship between levels of Cyp2r1 mRNA and serum 25(OH)D concentrations as well as between Cyp2R1 mRNA and the ratio of circulating 25(OH)D3 to cholecalciferol (p < 0.0001). Using linear regression we determined a curve with 25(OH)D3/cholecalciferol versus normalized Cyp2R1 mRNA abundance with an R2 value of 0.85. Finally, we performed ex vivo activity assays of isolated livers and found that obese mice generated significantly less 25(OH)D3 than lean mice (p < 0.05). Our findings indicate that expression of CYP2R1 is reduced in obesity and accounts in part for the decreased circulating 25(OH)D. © 2019 American Society for Bone and Mineral Research.
Diagnostic Thresholds for Androgen-Producing Tumors or Pathologic Hyperandrogenism in Women by Use of Total Testosterone Concentrations Measured by Liquid Chromatography-Tandem Mass Spectrometry
Sharma, Anu , Kapoor, Ekta , Chang, Alice Y. , Erickson, Dana , Singh, Ravinder

Mayo Clinic

Clinical Chemistry | August 1, 2018 | Volume: 64 | Issue: 11 | Pages: 1636-1645

10.1373/clinchem.2018.290825 | PMID 30068692 Get It

Abstract BACKGROUND Previously defined thresholds for total testosterone (TT) concentrations to screen for androgen-producing tumors (APTs) have used RIA, which can be less accurate in women. We aimed to define diagnostic thresholds to screen for APTs or postmenopausal pathologic hyperandrogenism using TT concentrations measured by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS). METHODS We performed a retrospective cohort study on all women with TT ≥3.5 nmol/L and all postmenopausal women presenting with hyperandrogenism between 2004 and 2014 at the Mayo Clinic in Rochester, MN. RESULTS Of the 369 women with TT ≥3.5 nmol/L, 89 were included and subdivided into 3 groups based on their clinical diagnosis [21 (24%), APT; 16 (18%), postmenopausal pathologic hyperandrogenism; 52 (58%), polycystic ovary syndrome]. The source of the APT was more frequently ovarian (81%, n = 17) than adrenal (19%, n = 4). The diagnostic threshold using ROC analysis for TT to identify APT in women with severe biochemical hyperandrogenemia was ≥5.1 nmol/L (sensitivity, 90%; specificity, 81%). In a second analysis of a cohort of postmenopausal women only presenting with symptoms or signs of hyperandrogenism, median TT was significantly higher in the postmenopausal pathologic hyperandrogenism group (APT and ovarian hyperthecosis) vs the idiopathic hyperandrogenism group (4.9 vs 0.8 nmol/L; P < 0.01). In postmenopausal women, the diagnostic threshold for pathologic hyperandrogenism was TT ≥2.2 nmol/L (sensitivity, 100%; specificity, 86%). CONCLUSIONS The diagnostic threshold for TT concentration as measured by LC-MS/MS to identify APT in women with biochemical severe hyperandrogenemia was TT ≥5.1 nmol/L. In postmenopausal women, the diagnostic threshold for pathologic hyperandrogenism was lower (TT ≥2.2 nmol/L).
Anogenital distance is determined during early gestation in humans
Jain, Viral G. , Goyal, Vaibhav , Chowdhary, Vikas , Swarup, Namita, Singal, Arbinder , Shekhawat, Prem , Singh, Ravinder J.

Mayo Clinic

Human Reproduction | July 30, 2018 | Volume: 33 | Issue: 9 | Pages: 1619-1627

10.1093/humrep/dey265 | PMID 30124868 Get It

Development of Vitamin D Toxicity from Overcorrection of Vitamin D Deficiency: A Review of Case Reports
Galior, Kornelia , Grebe, Stefan K., Grebe, Stefan, Singh, Ravinder J.

Mayo Clinic

Nutrients | July 24, 2018 | Volume: 10 | Issue: 8 | Pages: 953

10.3390/nu10080953 | PMID 30042334 Get It

Over the past two decades, vitamin D level measurements have become some of the most frequently ordered tests in the laboratory. This increase is due to a growing awareness of widespread vitamin D deficiency and scientific data suggesting the beneficial effects of vitamin D in various diseases. A literature search was carried out in PubMed for cases reporting vitamin D intoxication and overdose. Thirteen articles were included in this review. Intoxication was severe in the reported cases. Patients presented with serum vitamin D concentrations ranging between 150 and 1220 ng/mL and serum calcium concentrations between 11.1 and 23.1 mg/dL. Most of the reported patients showed symptoms of vitamin D toxicity such as vomiting, dehydration, pain, and loss of appetite. The underlying causes included manufacturing errors, overdosing by patients or prescribers, and combinations of these factors. Our literature search highlights the fact that even though vitamin D intoxication is rare, it does occur and therefore patients and prescribers should be more cognizant of the potential dangers of vitamin D overdose.
Sex differences in NSAID‐induced perturbation of human intestinal barrier function and microbiota
Edogawa, Shoko, Peters, Stéphanie , Jenkins, Gregory D. , Gurunathan, Sakteesh, Sundt, Wendy, Johnson, Stephen , Lennon, Ryan J. , Dyer, Roy B. , Camilleri, Michael , Kashyap, Purna , Farrugia, Gianrico, Grover, Madhusudan , Peters, Stephanie A, Gurunathan, Sakteesh V, Sundt, Wendy J., Johnson, Stephen, Farrugia, Gianrico , Chen, Jun , Singh, Ravinder J.

Mayo Clinic

The FASEB Journal | June 13, 2018 | Volume: 32 | Issue: 12 | Pages: 6615-6625

10.1096/fj.201800560r | PMID 29897814 Get It

ABSTRACT Intestinal barrier function and microbiota are integrally related and play critical roles in maintenance of host physiology. Sex is a key biologic variable for several disorders. Our aim was to determine sex‐based differences in response to perturbation and subsequent recovery of intestinal barrier function and microbiota in healthy humans. Twenty‐three volunteers underwent duodenal biopsies, mucosal impedance, and in vivo permeability measurement. Permeability testing was repeated after administration of indomethacin, then 4 to 6 wk after its discontinuation. Duodenal and fecal microbiota composition was determined using 16S rRNA amplicon sequencing. Healthy women had lower intestinal permeability and higher duodenal and fecal microbial diversity than healthy men. Intestinal permeability increases after indomethacin administration in both sexes. However, only women demonstrated decreased fecal microbial diversity, including an increase in Prevotella abundance, after indomethacin administration. Duodenal microbiota composition did not show sex‐specific changes. The increase in permeability and microbiota changes normalized after discontinuation of indomethacin. In summary, women have lower intestinal permeability and higher microbial diversity. Intestinal permeability is sensitive to perturbation but recovers to baseline. Gut microbiota in women is sensitive to perturbation but appears to be more stable in men. Sex‐based differences in intestinal barrier function and microbiome should be considered in future studies.—Edogawa, S., Peters, S. A., Jenkins, G. D., Gurunathan, S. V., Sundt, W. J., Johnson, S., Lennon, R. J., Dyer, R. B., Camilleri, M., Kashyap, P. C., Farrugia, G., Chen, J., Singh, R. J., Grover, M. Sex differences in NSAID‐induced perturbation of human intestinal barrier function and microbiota. FASEB J. 32, 6615–6625 (2018). www.fasebj.org
In Reply
Hines, Jolaine, Grebe, Stefan K., Grebe, Stefan K G, Bancos, Irina , Singh, Ravinder

Mayo Clinic

Clinical Chemistry | May 30, 2018 | Volume: 64 | Issue: 8 | Pages: 1258-1259

10.1373/clinchem.2018.290205 | PMID 29848546 Get It